IDO1 and cancer: Several studies have shown high IDO1 expression was associated with poor prognosis in a variety of cancer types.[21] Undoubtedly, IDO1 is an ideal target for cancer immunotherapy, several IDO1 inhibitors, including 1‐methyl‐D, L‐tryptophan, and indoximod, have entered clinical trials.